Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data
SAN FRANCISCO, Nov. 21, 2022 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced that Cory R. Nicholas, Ph.D., Neurona’s president and chief executive officer, was invited to present an overview of Neurona’s regenerative cell therapy technology, proprietary manufacturing process, cell delivery system, and preclinical […]
The First Stem Cell Model of PTSD: What It Means For Research and Treatment
How are stem cells changing our understanding of PTSD? Post-traumatic stress disorder (PTSD) is a psychiatric disorder that may occur after experiencing a traumatic event, but only for a minority of people. Understanding why certain individuals are susceptible to PTSD has been a challenge, as scientists lacked the means to capture how the neurons of […]
Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human Pluripotent Stem Cells
MINNEAPOLIS, Nov. 17, 2022 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of a single-cell cloning workflow study using the Namocell™ Single Cell Dispenser in Nature Protocols: Efficient and safe single-cell cloning of human pluripotent stem cells using the chroman 1, emricasan, polyamines, and trans-ISRIB (CEPT) cocktail. This publication outlines a robust and scalable workflow for cloning human pluripotent stem cells […]
The future of ALL treatment: moving away from stem cell transplantation
Nicholas Short, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into future treatment approaches in acute lymphoblastic leukemia (ALL), highlighting the growing role of inotuzumab ozogamicin, blinatumomab, and CAR-T cells. Dr Short further explains the importance of moving away from stem cell transplantation and bringing novel agents and CAR-T therapy […]
ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its initial Phase 2 studies for high-risk leukemias and myelodysplastic syndromes (MDS). ECT-001 Cell Therapy, ExCellThera’s most advanced investigational drug, combines the proprietary molecule UM171 and an […]
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the first patient has been enrolled in the company’s BEACON trial. BEACON is an open-label, single-arm, multicenter, Phase 1/2 clinical trial designed to evaluate the safety and efficacy of BEAM-101 in […]
What makes a stem cell a stem cell and how does it go bad?
Dr. John Dick was awarded the Canada Gairdner International Award 2022 “For the discovery and characterization of leukemic stem cells, providing insights into the understanding, diagnosis and treatment of acute myeloid leukemia.” He presented his award-winning research at the 2022 Gairdner Science Week Laureate Lectures.
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
NEW YORK, Nov. 10, 2022 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that the company has received a refusal to file letter from the U.S. Food and Drug Administration (FDA) regarding the company’s New Biologics License Application (BLA) for NurOwn for the treatment of ALS. The […]
Grant Awarded to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer
NEW YORK, Nov. 9, 2022 /PRNewswire/ — The DeGregorio Family Foundation with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative (GEMINI) has awarded $250,000 to Saar Gill, MD, PhD, of the University of Pennsylvania, to improve immunotherapy in gastroesophageal cancer by using the tools of genetic engineering to modify human blood-forming stem cells to produce highly specialized cancer-eating cells called […]
ExCellThera announces 100th patient treated with UM171-expanded cell therapy
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) — ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that its proprietary ECT-001 Cell Therapy has been administered to 100 patients. ECT-001 Cell Therapy is an investigational UM171-expanded cord blood cell therapy being evaluated in trials across multiple adult and pediatric hematological […]